

2004 Grants

Investigator	Institution	Project Title	Grant Duration	Amt Granted
Sergei Atamas, M.D., Ph.D.	University of Maryland School of Medicine Baltimore, Md.	The Role of PARC in Lung Fibrosis – From In Vitro to In Vivo Research	Two Years	\$150,000
Edwin Chan, M.B., Ch.B.	New York University School of Medicine New York, N.Y.	Purinergic Modulation of Dermal Fibrosis	One Year	\$50,000
Susan Croll, Ph.D.	Queens College – CUNY Flushing, N.Y.	Inflammation Induced by Sympathetic Overactivation: Evaluation of a Potential Animal Model for Scleroderma Features and Etiology	One Year	\$50,000
Asish Ghosh, Ph.D.	University of Illinois at Chicago, Chicago, Ill.	Repression of TGF- β Signaling by PPAR-?: Novel Approach to Controlling Fibrosis	Two Years	\$150,000
Richard Gomer, Ph.D.	Rice University Houston, TX	Testing Serum Amyloid P as a Diagnostic and Therapeutic	Two Years	\$150,000
Robert Lafyatis, M.D.	Boston University Medical Center, Boston, Mass.	Fibrillin-binding Matrix and BMPs in TSK Mice and Scleroderma	Two Years	\$150,000
Irina Luzina, M.D., Ph.D.	Baltimore VA Medical Center, Baltimore, Md.	G-Protein-Coupled Signaling From PARC Receptor in Lung Fibroblasts	Three Years	\$150,000
Karen Lyons, Ph.D.	University of California Los Angeles, Calif.	CTGF in Scleroderma	Two Years	\$150,000
Yasuji Mori, M.D., Ph.D.	University of Illinois at Chicago, Chicago, Ill.	Modulation of Fibrotic Responses by a Novel TGF- β Receptor Kinase Inhibitor in Vitro and in Vivo	Two Years	\$150,000
Elena Tourkina, Ph.D.	Medical University of South Carolina Charleston, S.C.	Caveolin-1 in Scleroderma Lung Disease	Two Years	\$150,000
Xiadong Zhou, M.D.	University of Texas Health Science Center Houston, TX	Regulation of SPARC & CTGF in Scleroderma Fibroblasts	Three Years	\$150,000

	Total Granted 2004:	\$1,450,000
--	---------------------	-------------

All grants funded by the Scleroderma Foundation.